BioAffinity Technologies Inc (NASDAQ: BIAF)’s stock price has gone rise by 4.65 in comparison to its previous close of 0.22, however, the company has experienced a 5.73% increase in its stock price over the last five trading days. prnewswire.com reported 2025-05-07 that JERSEY CITY, N.J., May 7, 2025 /PRNewswire/ — WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, has closed its previously announced best efforts offering of securities as described below for aggregate gross proceeds to the Company of $3.25 million, before deducting agent fees and other estimated expenses payable by the company.
Is It Worth Investing in BioAffinity Technologies Inc (NASDAQ: BIAF) Right Now?
Company’s 36-month beta value is 2.50.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for BIAF is 11.16M, and currently, short sellers hold a 2.59% ratio of that floaft. The average trading volume of BIAF on May 15, 2025 was 9.90M shares.
BIAF’s Market Performance
BIAF stock saw a decrease of 5.73% in the past week, with a monthly decline of -55.00% and a quarterly a decrease of -71.52%. The volatility ratio for the week is 15.41%, and the volatility levels for the last 30 days are 16.03% for BioAffinity Technologies Inc (BIAF). The simple moving average for the last 20 days is -41.26% for BIAF’s stock, with a simple moving average of -79.40% for the last 200 days.
BIAF Trading at -46.67% from the 50-Day Moving Average
After a stumble in the market that brought BIAF to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -92.47% of loss for the given period.
Volatility was left at 16.03%, however, over the last 30 days, the volatility rate increased by 15.41%, as shares sank -54.89% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -31.82% lower at present.
During the last 5 trading sessions, BIAF rose by +5.73%, which changed the moving average for the period of 200-days by -91.70% in comparison to the 20-day moving average, which settled at $0.3830. In addition, BioAffinity Technologies Inc saw -75.27% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for BIAF
Current profitability levels for the company are sitting at:
- -0.96 for the present operating margin
- 0.34 for the gross margin
The net margin for BioAffinity Technologies Inc stands at -0.97. The total capital return value is set at -2.63. Equity return is now at value -242.44, with -122.70 for asset returns.
Based on BioAffinity Technologies Inc (BIAF), the company’s capital structure generated 0.37 points at debt to capital in total, while cash flow to debt ratio is standing at -4.84. The debt to equity ratio resting at 0.58. The interest coverage ratio of the stock is -96.82.
Currently, EBITDA for the company is -8.33 million with net debt to EBITDA at -0.05. When we switch over and look at the enterprise to sales, we see a ratio of 0.48. The receivables turnover for the company is 8.22for trailing twelve months and the total asset turnover is 1.44. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.87.
Conclusion
In a nutshell, BioAffinity Technologies Inc (BIAF) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
